AstraZeneca PLC (FRA:ZEG)
128.75
-0.45 (-0.35%)
At close: Jun 11, 2025, 10:00 PM CET
AstraZeneca Revenue
AstraZeneca had revenue of $13.59B USD in the quarter ending March 31, 2025, with 7.17% growth. This brings the company's revenue in the last twelve months to $54.98B, up 15.48% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$54.98B
Revenue Growth
+15.48%
P/S Ratio
3.95
Revenue / Employee
$583.05K
Employees
94,300
Market Cap
200.77B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.15B |
Siemens Aktiengesellschaft | 77.82B |
Deutsche Telekom AG | 120.25B |
Allianz SE | 109.03B |
Rheinmetall AG | 10.48B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
Siemens Energy AG | 37.44B |
Siemens Healthineers AG | 23.14B |
AstraZeneca News
- 2 days ago - I attended the world's biggest cancer conference. Doctors gave standing ovations to 2 major breakthroughs. - Business Insider
- 3 days ago - Merck wins FDA nod for RSV shot for infants, challenging Sanofi/ AstraZeneca - Seeking Alpha
- 3 days ago - What's Going On With IonQ Shares Monday? - Benzinga
- 3 days ago - FDA approves Mercks RSV shot for infants, ramping up competition with Sanofi and AstraZeneca - CNBC
- 4 days ago - DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - Benzinga
- 4 days ago - IonQ, AstraZeneca, Nvidia and AWS show quantum-accelerated drug development workflow - Seeking Alpha
- 6 days ago - AstraZeneca: Fascinating Company With Lofty Ambitions - Just Not A Buy Yet - Seeking Alpha
- 7 days ago - AstraZeneca’s £1 Billion Cambridge Hub Fuels UK Biotech Surge - ABC Money